Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)”

77 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 77 results

Testing effectiveness (Phase 2)Ended earlyNCT04631744
What this trial is testing

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 4
Early research (Phase 1)Study completedNCT02740985
What this trial is testing

Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid MalignanciesNon-Small Cell Lung Cancer (NSCLC)Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)+1 more
AstraZeneca 313
Testing effectiveness (Phase 2)Study completedNCT03179410
What this trial is testing

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Who this might be right for
Prostate Cancer
Andrew J. Armstrong, MD 15
Testing effectiveness (Phase 2)Study completedNCT01360840
What this trial is testing

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
EMD Serono 180
Testing effectiveness (Phase 2)Looking for participantsNCT05413850
What this trial is testing

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Blue Earth Therapeutics Ltd 82
Large-scale testing (Phase 3)Ended earlyNCT01083615
What this trial is testing

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castrate-Resistant Prostate CancerHormone Refractory Prostate Cancer
Achieve Life Sciences 14
Testing effectiveness (Phase 2)WithdrawnNCT02035124
What this trial is testing

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Who this might be right for
Advanced Prostate Cancer
SCRI Development Innovations, LLC
Testing effectiveness (Phase 2)Study completedNCT02711956
What this trial is testing

ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics 75
Testing effectiveness (Phase 2)Study completedNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Early research (Phase 1)Active Not RecruitingNCT07214961
What this trial is testing

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer (CRPC)Metastatic Castrate Resistant Prostate Cancer (mCRPC)
ARTBIO Inc. 80
Early research (Phase 1)Not Yet RecruitingNCT07090369
What this trial is testing

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Peter MacCallum Cancer Centre, Australia 20
Testing effectiveness (Phase 2)Looking for participantsNCT07414940
What this trial is testing

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Who this might be right for
Metastatic Castration-resistant Prostate CancerMetastatic Prostate CancerProstate Cancer
University College, London 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05067140
What this trial is testing

ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Novartis Pharmaceuticals 164
Testing effectiveness (Phase 2)Ended earlyNCT01385293
What this trial is testing

BKM120 in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic (Spread to Other Areas of the Body)
Andrew J. Armstrong, MD 30
Testing effectiveness (Phase 2)Study completedNCT04495179
What this trial is testing

AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Who this might be right for
Progressive Metastatic Castrate-Resistant Prostate Cancer
AstraZeneca 30
Large-scale testing (Phase 3)Active Not RecruitingNCT06764485
What this trial is testing

Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Celgene 960
Testing effectiveness (Phase 2)Looking for participantsNCT06702995
What this trial is testing

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate-Resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Evopoint Biosciences Inc. 307
Testing effectiveness (Phase 2)Study completedNCT02463799
What this trial is testing

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 36
Testing effectiveness (Phase 2)Study completedNCT01818986
What this trial is testing

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castrate-resistant Prostate CancermCRPC
University of Texas Southwestern Medical Center 20
Testing effectiveness (Phase 2)Ended earlyNCT01681433
What this trial is testing

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Who this might be right for
Prostate CancerMetastatic Castrate-Resistant Prostate CancerPSA
Costantine Albany 72
Next Page